8-K: Cadrenal Acquires eXIthera's FXIa Inhibitor Portfolio

Cadrenal Therapeutics significantly expands its anticoagulation pipeline by acquiring eXIthera Pharmaceuticals' Factor XIa inhibitor assets, including Phase 2-ready Frunexian.

Summary

• Cadrenal Therapeutics, Inc. acquired all rights, title, and interests in assets related to Frunexian (EP-7041) and EP-7327, and other compounds, from eXIthera Pharmaceuticals, Inc. on September 12, 2025.
• The acquired assets include intellectual property, regulatory filings, clinical and non-clinical data, market analyses, commercialization plans, inventory, books and records, and the exclusive license agreement with Sichuan Haisco Pharmaceutical Co., Ltd. for Frunexian in China.
• The purchase price consists of a $50,000 cash payment for transaction closing costs, contingent milestone payments up to $15 million, and royalty payments.
• Contingent milestone payments are tied to clinical and regulatory achievements, including first patient dosed in Phase 1, Phase 2, and Phase 3 studies, and FDA New Drug Application (NDA) approvals for Frunexian/Other IV Compound and EP-7327/Other Oral Compound.
• Royalty payments include 2% of Annual Net Sales of pharmaceutical products containing the acquired compounds (excluding China) and 50% of all royalties Cadrenal receives from Haisco under the existing license agreement.
• Milestone and royalty payments can be made in cash, common stock, or a combination, at Cadrenal's discretion, with specific conditions for stock issuance.

Sentiment

Score: 8

Explanation: The acquisition significantly expands the company's pipeline with novel, high-potential assets in a large market, reinforcing its strategic vision to become a leader in anticoagulation therapy. This move is strategically sound and positions the company for future growth, despite the inherent risks of drug development and potential for equity dilution.

Positives

• Significantly enhances the company's pipeline by adding novel assets in both acute and chronic anticoagulation settings.
• Acquired compounds, Frunexian (Phase 2-ready IV Factor XIa inhibitor) and EP-7327 (IND-ready oral Factor XIa inhibitor), address large and underserved segments of the $38 billion global anticoagulation market.
• Positions Cadrenal as the only company developing both a novel Vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants.
• Factor XIa inhibitors offer high potency, selectivity, and tunable pharmacokinetics, potentially reducing bleeding risk compared to current broad-acting anticoagulants.
• The acquisition reinforces Cadrenal's long-term vision of becoming a category leader in anticoagulation.
• The deal structure allows Cadrenal to focus capital deployment on advancing clinical development of both tecarfarin and the newly acquired assets.

Negatives

• Milestone payments are contingent upon future clinical and regulatory achievements, meaning there is no guarantee they will be fully realized.
• The company has the discretion to pay milestone and royalty payments in common stock, which could lead to shareholder dilution.

Risks

• Actual results may differ materially and adversely from forward-looking statements due to various risks and uncertainties.
• Risks include the ability to successfully develop and commercialize product candidates, raise capital when needed, and navigate the competitive environment.
• Specific risks relate to Cadrenal's ability to deliver differentiated therapeutics, the potential of EP-7327, addressing critical gaps in treatment, the payment of milestone payments and royalties, and successfully advancing tecarfarin and acquired assets into clinical practice.
• Risks are detailed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Future Outlook

The company plans to advance the clinical development of both tecarfarin and the newly acquired Factor XIa inhibitor assets. This includes initiating a Phase 2 study for tecarfarin in ESKD+AFib patients transitioning to dialysis in Q1 2026, a Phase 2 study for tecarfarin in LVAD patients in Q4 2026, and advancing CMC development for Frunexian in preparation for a Phase 2 study in complex cardiac surgery in Q1 2027. The strategic goal is to deliver differentiated therapeutics across the entire spectrum of cardiovascular thrombotic risk.

Management Comments

• "These newly acquired assets will expand Cadrenal's capabilities in an effort to address even more critical gaps in current antithrombotic treatment, especially for patients for whom current therapies are unreliable or carry excessive bleeding risk."
• "This acquisition reinforces Cadrenal's long-term vision of becoming a category leader in anticoagulation."
• "With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk."

Industry Context

The global anticoagulation market is estimated at $38 billion, with significant unmet needs due to limitations of current therapies like warfarin (bleeding, monitoring, drug interactions), DOACs (bleeding, lack of monitoring/reversibility, failure in mechanical heart valves), and heparin (bleeding, infusion, HIT/HITTS). Factor XIa inhibition is highlighted as one of the most active and exciting areas of current thrombosis research, offering a mechanism to prevent thrombosis without broadly increasing bleeding risk. The industry has seen over $4 billion in recent strategic investments in next-generation FXI inhibitors by major pharmaceutical companies, validating Cadrenal's strategic move into this space.

Comparison to Industry Standards

• Frunexian is presented as the first and only IV Factor XIa inhibitor for acute care, differentiating it from other FXIa inhibitors primarily developed for chronic indications or with different administration routes.
• Other notable Factor XIa inhibitors in development include Milvexian (BMS/JNJ, oral, Phase 3 for acute coronary syndrome, atrial fibrillation, secondary stroke prevention), Asundexian (Bayer, oral, Phase 3 for secondary stroke prevention, with an Afib trial terminated), SHR2285 (Hengrui Pharm., oral, Phase 2 for VTE prevention), Abelacimab (NVS, antibody, SC/IV, Phase 3 for Afib, cancer-associated VTE), Osocimab (Bayer, antibody, IV, Phase 2 for thrombosis prevention in TKR, chronic kidney disease), Xisomab 3G3 (Bayer, antibody, IV, Phase 2 for cancer associated thrombosis, chronic hemodialysis in ESKD), and Fesomersen (Ionis, antisense oligonucleotide, SC, Phase 2 for ESKD).

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline expansion and entry into a high-growth therapeutic area, but also potential for dilution if milestone payments are made in common stock.
• Patients: New, potentially safer and more effective treatment options for acute and chronic thrombotic conditions, especially for those with unmet needs or high bleeding risk.
• Employees: Opportunities for growth and involvement in a broader and more diversified research and development pipeline.

Next Steps

• Initiate Phase 2 study for Tecarfarin in End-stage Kidney Disease (ESKD) patients with Atrial Fibrillation (AFib) transitioning to dialysis in Q1 2026.
• Initiate Phase 2 study for Tecarfarin in Left Ventricular Assist Device (LVAD) patients in Q4 2026.
• Advance CMC (Chemistry, Manufacturing, and Controls) development for Frunexian.
• Initiate Phase 2 study for Frunexian in complex cardiac surgery in Q1 2027.

Key Dates

Recommendation

The acquisition of eXIthera's Factor XIa inhibitor portfolio represents a highly strategic and transformative move for Cadrenal Therapeutics. It significantly diversifies and strengthens the company's pipeline with assets targeting large, underserved segments of the global anticoagulation market, estimated at $38 billion. The Factor XIa inhibition mechanism is a cutting-edge area of thrombosis research, offering the potential for effective anticoagulation with a reduced bleeding risk compared to current standards. This positions Cadrenal uniquely as a developer of both novel VKAs and FXIa inhibitors. While milestone payments could involve equity, the long-term growth potential from these differentiated therapeutics, coupled with existing Orphan Drug and Fast Track designations for tecarfarin, suggests a strong upside for investors willing to take on biopharmaceutical development risk.

Keywords

Cadrenal Therapeutics, eXIthera Pharmaceuticals, Frunexian, EP-7327, Factor XIa inhibitor, anticoagulation, biopharmaceutical, pipeline expansion, drug acquisition, cardiovascular, thrombosis, tecarfarin, clinical trials, FDA approval, orphan drug, fast track